Accuray Incorporated has entered into agreements with Samsung HME America Inc., doing business as Samsung NeuroLogica, to explore advanced volumetric imaging for its CyberKnife System. The collaboration combines Samsung NeuroLogica’s mobile computed tomography and imaging expertise with Accuray’s robotic radiosurgery, precision treatment delivery and motion-management technology. The companies aim to bring more anatomical information closer to treatment decisions, potentially supporting future workflows that adapt radiation treatment to changes in a patient’s anatomy. The Royal Marsden NHS Foundation Trust will be the first participating center worldwide, while development proceeds in phases and no commercial product has been announced. Accuray shares rose 42.07% to $0.3056 in Monday premarket trading, with volume reaching 152.824 million shares versus a 100-day average of 1.195 million. The company’s latest results showed a quarterly loss of 2 cents per share, revenue of $100.9 million and adjusted EBITDA of $12.9 million.